SYRA
Syra Health Corp
Next earnings Aug 10, 2026
Last earnings +11.2% on 2026-05-07
$0.54
▲ 0.00%$0.54▲ +434.65%
over 1Y
L $0.06EODHDH $0.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+10.3%
1M+10.8%
3M+229.3%
YTD+518.6%
1Y+434.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.32x); but revenue declined -9.5% YoY.
Revenue (FY2025) $7.23M · FY2025
Syra Health Corp shows $7.23M in FY2025 revenue (-9.5% YoY), a -12.4% net margin, and -42.7% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $5.62M | $5.52M | $7.98M | $7.23M |
| Gross profit | $1.06M | $1.41M | $1.65M | $2.49M |
| Operating income | -$2.09M | -$2.89M | -$3.76M | -$904K |
| Net income | -$2.12M | -$2.94M | -$3.76M | -$896K |
| Diluted EPS | -$0.70 | -$0.60 | -$0.50 | -$0.08 |
| Net margin | -37.7% | -53.3% | -47.1% | -12.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.51M
EV / EBITDA—
EV / Sales0.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-14.6%
FCF yield-7.3%
Quality & risk
ROIC (est.)-34.0%
Free cash flow-$448K
Total debt—
Net cash$1.61M
Altman Z-Score2.96 grey
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-27). Worth a closer look.
Recent filings
all on EDGAR ↗DEFA14AFiling2026-06-01open ↗ARSPeriod ending 2025-12-312026-06-01open ↗DEF 14APeriod ending 2026-06-012026-06-01open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗10-K/APeriod ending 2025-12-312026-04-27open ↗10-KPeriod ending 2025-12-312026-03-12open ↗8-KPeriod ending 2026-03-122026-03-12open ↗4Period ending 2026-01-052026-02-03open ↗SCHEDULE 13DFiling2026-01-16open ↗3Period ending 2026-01-052026-01-14open ↗3Period ending 2025-08-132026-01-13open ↗
Frequently asked
- Is Syra Health Corp (SYRA) a buy?
- SYRA currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.32x); but revenue declined -9.5% YoY.
- What is Syra Health Corp's quality score?
- SYRA scores 58.45098039215686/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001922335, latest 10-Q filed 2026-05-07) · EODHD · as of 6/27/2026, 5:28:20 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.